The rapid scale-up of research on coronavirus disease 2019 (COVID-19) has spawned a
large number of potential vaccines and immunotherapies, accompanied by a …

Understanding the earliest immune responses following HIV infection is critical to inform
future vaccines and therapeutics. Here, we review recent prospective human studies in at …

Increasingly, antibodies are being used to treat and prevent viral infections. In the context of
HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser …

Previously, we showed that substitution of HIV-1 envelope (Env) residue 375-Ser by bulky
aromatic residues enhances binding to rhesus CD4 and enables primary HIV-1 Envs to …

African green monkeys (AGMs) are natural hosts of SIV whose infection does not progress to
AIDS. Since early events of infection may be critical to pathogenesis in nonnatural hosts, we …

Clinical trials for HIV prevention can require knowledge of infection times to subsequently
determine protective drug levels. Yet, infection timing is difficult when study visits are sparse …

Genetically barcoded viral populations are powerful tools for evaluating the overall viral
population structure as well as assessing the dynamics and evolution of individual lineages …

Human immunodeficiency virus (HIV) remains a leading cause of global morbidity with the
highest burden in Sub-Saharan Africa (SSA). For reasons that are incompletely understood …

The initial immune response to HIV determines transmission. However, due to technical
limitations we still do not have a comparative map of early mucosal transmission events. By …

HIV infection requires lifelong antiretroviral therapy (ART) to control disease progression.
Although ART has greatly extended the life expectancy of persons living with HIV (PWH) …